Categories
Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Dosage Modifications-3)

In this article we will discuss Durvalumab (Dosage Modifications-3)

In this article, we will discuss Durvalumab (Dosage Modifications-3). So, let’s get started.

Hepatitis with no tumor involvement of the liver

  • ALT or AST increases to more than 3 and up to 8 times the ULN or total bilirubin increases to more than 1.5 and up to 3 times ULN – Withhold
  • ALT or AST increases to more than 8 times ULN or total bilirubin increases to more than 3 times the ULN – Permanently discontinue

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.